Trial Profile
NEMO1: An Open Label Exploratory Dose Finding and Pharmacokinetic Clinical Trial of Bumetanide for the Treatment of Neonatal Seizure Using Medication Off-patent
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 30 Sep 2017
Price :
$35
*
At a glance
- Drugs Bumetanide (Primary) ; Phenobarbital
- Indications Neonatal seizures
- Focus Adverse reactions
- Acronyms NEMO-1
- 01 May 2015 Status changed from completed to discontinued according to results published in the Lancet Neurology.
- 01 Jun 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Sep 2011 New trial record